© 2004 BMJ Publishing Group Ltd & British Thoracic Society
LUNG ALERT
Neurodevelopmental defects after steroid treatment of premature lung disease
Paediatric Specialist Registrar, Darent Valley Hospital, Dartford, UK; donniebird@hotmail.com
| The first 150 words of the full text of this article appear below. |
Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethsaone therapy for lung disease of prematurity. N Engl J Med 2004;350:130413.
There has been much controversy in recent years regarding the early use of postnatal corticosteroids to treat preterm infants with respiratory distress syndrome (RDS). Short term respiratory benefits must be weighed against the potential for detrimental neurodevelopmental effects.
This study reports follow up data on growth, neurological and motor function, cognition, and school performance of two groups of ex-preterm infants assessed when reaching school age. In the original study, 262 preterm infants with severe RDS were randomly allocated to receive either early postnatal dexamethasone or placebo. The study had reported a significant reduction in chronic lung disease in the dexamethasone treated group without excess mortality. The children followed up at school age were the survivors of the original study. At school age
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
